Pharma

Dr. Reddy’s

Latest : Dr Reddy’s launched Hevaxin, a novel recombinant hepatitis-E vaccine approved in India — commercial launch announced. Why it matters: New product launches can add revenue and diversify pipelines — but scale and pricing determine impact. Regulatory approvals reduce clinical/regulatory risk for that product. Beginner tip: For pharma stocks, separate near-term revenue news (launches/approvals) from longer-term R&D pipeline prospects. One vaccine launch is positive but evaluate market size and margins.